scholarly journals A Novel Optical Bioimaging Method for Direct Assessment of Ovarian Cancer Chemotherapy Response at Laparoscopy

2016 ◽  
Vol 15 ◽  
pp. CIN.S40660 ◽  
Author(s):  
Alexandros Laios ◽  
Davide Volpi ◽  
Rajeev Kumar ◽  
Zoe Traill ◽  
Borivoj Vojnovic ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Unit Length ◽  
Evaluation Criteria ◽  
Advanced Ovarian Cancer ◽  
Software Tool ◽  
Lesion Size ◽  
Chemotherapy Response ◽  
Direct Assessment ◽  
Before And After ◽  
Image Pixels

In patients with advanced ovarian cancer (AOC), additional imaging of disseminated disease at laparoscopy could complement conventional imaging for estimation of chemotherapy response. We developed an image segmentation method and evaluated its use in making accurate and objective measurements of peritoneal metastases in comparison to Response Evaluation Criteria In Solid Tumors (RECIST) criteria. A software tool using a custom ImageJ macro-based approach was employed to estimate lesion size by converting image pixels into unit length. The software tool was tested as a proof-of-principle in an AOC patient with two isolated peritoneal deposits. Image analysis of representative laparoscopic snapshots before and after three cycles of neoadjuvant chemotherapy (NACT) revealed an average tumor nodule response ratio (TNRR) of 40% (partial response), which was in concordance with RECIST evaluation by computed tomography (CT). We demonstrated the feasibility of using this novel anatomical analysis for direct assessment of chemotherapy response in an AOC patient as an adjunct to RECIST criteria.

scholarly journals Comparative Proteomic Analysis of Advanced Ovarian Cancer Tissue to Identify Potential Biomarkers of Responders and Nonresponders to First-Line Chemotherapy of Carboplatin and Paclitaxel

2016 ◽  
Vol 8 ◽  
pp. BIC.S35775 ◽  
Author(s):  
Urmila Sehrawat ◽  
Ruchika Pokhriyal ◽  
Ashish Kumar Gupta ◽  
Roopa Hariprasad ◽  
Mohd Imran Khan ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Spectrometric Analysis ◽  
Cancer Tissue ◽  
Chemotherapy Response ◽  
Tissue Samples ◽  
Post Surgery ◽  
Dismal Prognosis ◽  
Apoptotic Activity ◽  
Potential Biomarkers

Conventional treatment for advanced ovarian cancer is an initial debulking surgery followed by chemotherapy combination of carboplatin and paclitaxel. Despite initial high response, three-fourths of these women experience disease recurrence with a dismal prognosis. Patients with advanced-stage ovarian cancer who underwent cytoreductive surgery were enrolled and tissue samples were collected. Post surgery, these patients were started on chemotherapy and followed up till the end of the cycle. Fluorescence-based differential in-gel expression coupled with mass spectrometric analysis was used for discovery phase of experiments, and real-time polymerase chain reaction, Western blotting, and pathway analysis were performed for expression and functional validation of differentially expressed proteins. While aldehyde reductase, hnRNP, cyclophilin A, heat shock protein-27, and actin are upregulated in responders, prohibitin, enoyl-coA hydratase, peroxiredoxin, and fibrin-β are upregulated in the nonresponders. The expressions of some of these proteins correlated with increased apoptotic activity in responders and decreased apoptotic activity in nonresponders. Therefore, the proteins qualify as potential biomarkers to predict chemotherapy response.

scholarly journals Chemotherapy Resistance in Advanced Ovarian Cancer Patients

2019 ◽  
Vol 11 ◽  
pp. 1179299X1986081 ◽  
Author(s):  
Ruchika Pokhriyal ◽  
Roopa Hariprasad ◽  
Lalit Kumar ◽  
Gururao Hariprasad
Keyword(s):  
Ovarian Cancer ◽  
Messenger Rna ◽  
Chemotherapy Resistance ◽  
Advanced Ovarian Cancer ◽  
Cellular Level ◽  
Chemotherapy Response ◽  
First Line ◽  
Debulking Surgery ◽  
Standard Management ◽  
Gynaecologic Malignancy

Ovarian cancer is the seventh most common gynaecologic malignancy seen in women. Majority of the patients with ovarian cancer are diagnosed at the advanced stage making prognosis poor. The standard management of advanced ovarian cancer includes tumour debulking surgery followed by chemotherapy. Various types of chemotherapeutic regimens have been used to treat advanced ovarian cancer, but the most promising and the currently used standard first-line treatment is carboplatin and paclitaxel. Despite improved clinical response and survival to this combination of chemotherapy, numerous patients either undergo relapse or succumb to the disease as a result of chemotherapy resistance. To understand this phenomenon at a cellular level, various macromolecules such as DNA, messenger RNA and proteins have been developed as biomarkers for chemotherapy response. This review comprehensively summarizes the problem that pertains to chemotherapy resistance in advanced ovarian cancer and provides a good overview of the various biomarkers that have been developed in this field.

Trabectedin for Women With Ovarian Carcinoma After Treatment With Platinum and Taxanes Fails

2005 ◽  
Vol 23 (9) ◽  
pp. 1867-1874 ◽  
Author(s):  
Cristiana Sessa ◽  
Filippo De Braud ◽  
Antonella Perotti ◽  
Jean Bauer ◽  
Giuseppe Curigliano ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Objective Response Rate ◽  
Response Rate ◽  
Objective Response ◽  
Evaluation Criteria ◽  
Advanced Ovarian Cancer ◽  
Treatment Interruption ◽  
Response Evaluation ◽  
Time To Progression ◽  
Platinum Sensitive

Purpose To assess the efficacy and toxicity of the marine-derived alkaloid trabectedin (ET-743) in patients with advanced ovarian cancer refractory to or experiencing disease relapse after platinum- and taxane-based chemotherapy. Patients and Methods Fifty-nine patients from four institutions either resistant (n = 30) or sensitive (n = 29) to prior platinum and taxanes were treated with a 3-hour infusion of trabectedin every 3 weeks. Patients were monitored weekly for toxicity and restaged every two cycles for response. Response was assessed according to Response Evaluation Criteria in Solid Tumors Group. Results The peer-reviewed objective response rate in platinum-sensitive patients was 43% (95% CI, 23% to 65%) with an estimated median time to progression of 7.9 months (95% CI, 7.5 to 14.1 months); in platinum-resistant patients two partial responses were observed. Responses were durable for up to 12.9 months (median, 5 months). The predominant toxicities at the recommended dose of 1,300 μg/m2 were neutropenia, asthenia, and self-limited increase of aminotransferases never requiring treatment interruption. Conclusion Trabectedin administered as a 3-hour infusion at 1,300 μg/m2 is a safe new drug with promising activity in relapsed ovarian cancer, showing a 43% objective response rate in patients with platinum-sensitive disease, which favorably compares with other salvage treatments and warrants additional development either alone or in combination.

The Value of Morphometry to Predict Chemotherapy Response in Advanced Ovarian Cancer

1989 ◽  
Vol 185 (5) ◽  
pp. 676-679 ◽  
Author(s):  
A.-R. Weger ◽  
Chr. Ludescher ◽  
G. Mikuz ◽  
G. Kemmler ◽  
R. Reitsamer ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Chemotherapy Response

scholarly journals Microbiological monitoring in patients with advanced ovarian cancer before and after cytoreductive surgery – a preliminary report

2017 ◽  
Vol 30 (4) ◽  
pp. 198-202 ◽  
Author(s):  
Maria Szymankiewicz ◽  
Krzysztof Koper ◽  
Konrad Dziobek ◽  
Zbigniew Kojs ◽  
Lukasz Wicherek
Keyword(s):  
Escherichia Coli ◽  
Ovarian Cancer ◽  
Cytoreductive Surgery ◽  
Large Bowel ◽  
Advanced Ovarian Cancer ◽  
Infectious Complications ◽  
E Coli ◽  
Microbiological Monitoring ◽  
Before And After ◽  
Etiological Agents

Abstract Multidrug-resistant organisms (MDROs) are becoming an increasing problem in hospitals. It is believed that screening patients for the incidence of MDROs prior to hospital admission not only allows for the proper management of infection following medical procedures, but can also potentially reduce the transmission of these bacteria to other patients. The aim of this study was to assess the carriers of selected MDROs in the gastrointestinal tract among patients with advanced ovarian cancer admitted to the hospital for cytoreductive surgery and to estimate the possible relationship between rectal colonization with these organisms and nosocomial infections. From December 2013 to May 2014, we evaluated the colonization with VRE (vancomycin-resistant Enterococcus), E. coli KPC+ (class A carbapenemase producing Escherichia coli), E. coli MBL+ (class B carbapenemase, metallo-ß lactamase producing Escherichia coli), and E. coli ESBL+ (extended-spectrum ß-lactamase producing Escherichia coli) in 42 patients. The patients were divided into two subgroups corresponding to the extent of their surgery: the first subgroup consisted of patients with large bowel resection (n=18) and the second subgroup of patients without resection (n=24). A rectal swab was taken within 24 hours of admission. Perioperative infectious complications were analyzed for the first 90 days following surgery with regard to the type of infection and the occurrence of examined MDROs. In our study, 2.4 % of all patients (23.8/1,000 hospitalizations) were colonized with ESBL - producing Escherichia coli: 0.0 % in the first subgroup and 4.2% in the second subgroup, respectively. We did not identify any patients who were colonized with VRE, E. coli MBL+, or E. coli KPC+. Surgical site infections were seen in 8 (19.1%) out of 42 patients. We were, therefore, unable to confirm a relationship between MDROs colonizing the large bowel and the etiological agents of perioperative infections. However, despite the lack of identification of MDROs as etiological agents of postoperative infection, the risk of serious infectious complications, combined with the changing epidemiological situation, means that microbiological monitoring should be performed in patients with ovarian cancer before and after cytoreductive surgery.

scholarly journals Assessment of glutathione S-transferaseM1 (GSTM1) and its polymorphisms GSTM1 null in the response to treatment with chemotherapy in advanced ovarian carcinoma

2011 ◽  
Vol 9 (3) ◽  
pp. 367-371 ◽  
Author(s):  
Gilberto Kendi Takeda ◽  
Daniela Batista Leite ◽  
Michele Gilvana Junqueira ◽  
Luiz Augusto Freire Lopes ◽  
Ismael Dale Cotrim Guerreiro da Silva ◽  
...  
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
World Health ◽  
Response To Treatment ◽  
Chemotherapy Response ◽  
Glutathione S Transferase ◽  
Response To Chemotherapy ◽  
Chemotherapeutic Treatment ◽  
Health Organization ◽  
Gstm1 Genotype

ABSTRACT Objective: To assess if the genotype of the glutathione S-transferase M1 (GSTM1) enzyme and its GSTM1 null polymorphism can influence the response to chemotherapeutic treatment of advanced ovarian cancer. Methods: Case-control study of 112 patients with advanced ovarian cancer submitted to chemotherapy during the period from January 1995 to December 2005. The tissue to study the GSTM1 genotype and its deletion came from surgical staging to treat ovarian cancer. The PCR product generates two distinct genotypes, characterized as positive and null. The response to chemotherapy was evaluated using the World Health Organization (WHO) criteria. Patients were classified as having: a) no response, b) a response. Results: The presence of GSTM1 or its GSTM1 null polymorphism did not influence the preoperative chemotherapy response. Among the patients who did respond, 88.9% presented with positive GSTM1 and 11.1% with null GSTM1. Among the patients that did not respond, 85.71% presented with positive GSTM1 and 14.29% with null GSTM1 (p = 0.825). GSTM1 and its GSTM1 null polymorphism had no influence on the postoperative response to chemotherapy. Among the patients who did respond, 80.65% presented with positive GSTM1 and 19.35% with null GSTM1. Among the patients who did not respond, 87.50% presented with positive GSTM1 and 12.5% with the null polymorphism (p = 0.553). Conclusion: No difference was observed in the response to treatment with chemotherapy in patients with advanced ovarian cancer, as to the GSTM1 genotype compared to its GSTM1 null polymorphism.

scholarly journals PRE-OPERATIVE HISTOLOGICAL PARAMETERS AS A PREDICTOR OF CHEMOTHERAPY RESPONSE IN ADVANCED OVARIAN CANCER

2021 ◽  
Vol 0 (0) ◽  
pp. 0-0
Author(s):  
abdelrahman Kamal abdelmouty Abdelrahman ◽  
Mahmoud El-Saied Melies ◽  
Rania Gaber Mohamed Aly ◽  
Neamat Elsayed Elsayed Hegazy ◽  
Noha Eid Mohammed
Keyword(s):  
Ovarian Cancer ◽  
Advanced Ovarian Cancer ◽  
Chemotherapy Response
Sign in / Sign up

Export Citation Format

Share Document